$GNLX
GENELUX Corp Stock $gnlx

$gnlx Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000149315223041151 Filed on November 14, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2022 Q3
Revenue	$0.00		$11.00M
YoY Change	-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.841M	$2.488M	$2.242M
YoY Change	309.37%	10.97%	93.78%
% of Gross Profit
Research & Development	$4.160M	$2.819M	$2.414M
YoY Change	68.56%	16.78%	66.6%
% of Gross Profit
Depreciation & Amortization	$95.00K	$134.0K	$138.0K
YoY Change	-31.16%	-2.9%	-66.75%
% of Gross Profit
Operating Expenses	$7.001M	$5.307M	$4.656M
YoY Change	121.41%	13.98%	78.66%
Operating Profit		-$5.307M	$6.344M
YoY Change		-183.65%
Interest Expense	$234.0K	-$38.00K	-$335.0K
YoY Change	-158.35%	-88.66%	-0.89%
% of Operating Profit			-5.28%
Other Income/Expense, Net		-$38.00K	-$335.0K
YoY Change		-88.66%
Pretax Income	-$6.767M	-$5.345M	$6.009M
YoY Change	93.62%	-188.95%	-304.11%
Income Tax	$0.00		$1.100M
% Of Pretax Income			18.31%
Net Earnings	-$6.767M	-$5.345M	$4.909M
YoY Change	93.62%	-208.88%	-266.75%
Net Earnings / Revenue			44.63%
Basic Earnings Per Share		-$0.20	$0.54
Diluted Earnings Per Share	-$0.25	-$0.20	$0.21
COMMON SHARES
Basic Shares Outstanding	26.72M shares	26.18M shares	9.118M shares
Diluted Shares Outstanding		26.21M shares	10.07M shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$23.19M	$29.87M	$1.370M
YoY Change	5741.56%	2080.22%
Cash & Equivalents	$9.418M	$29.87M	$1.370M
Short-Term Investments	$13.77M
Other Short-Term Assets	$1.012M	$1.310M	$1.491M
YoY Change	-32.31%	-12.14%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$24.20M	$31.18M	$2.861M
YoY Change	1179.23%	989.79%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.170M	$1.022M	$2.223M
YoY Change	-40.88%	-54.03%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$92.00K	$92.00K	$1.105M
YoY Change	-94.46%	-91.67%
Total Long-Term Assets	$3.690M	$2.893M	$3.328M
YoY Change	1.4%	-13.07%
TOTAL ASSETS
Total Short-Term Assets	$24.20M	$31.18M	$2.861M
Total Long-Term Assets	$3.690M	$2.893M	$3.328M
Total Assets	$27.89M	$34.07M	$6.189M
YoY Change	404.3%	450.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.784M	$4.009M	$5.352M
YoY Change	-44.15%	-25.09%
Accrued Expenses	$2.770M	$4.139M	$7.690M
YoY Change	-64.7%	-46.18%
Deferred Revenue
YoY Change
Short-Term Debt	$900.0K	$900.0K	$0.00
YoY Change	-9.27%
Long-Term Debt Due	$0.00	$607.0K	$8.346M
YoY Change	-100.0%	-92.73%
Total Short-Term Liabilities	$6.554M	$8.755M	$21.45M
YoY Change	-79.28%	-59.18%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$1.289M	$17.07M
YoY Change	-100.0%	-92.45%
Other Long-Term Liabilities	$1.866M	$1.289M
YoY Change
Total Long-Term Liabilities	$1.866M	$1.289M	$17.07M
YoY Change	-80.74%	-92.45%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.554M	$8.755M	$21.45M
Total Long-Term Liabilities	$1.866M	$1.289M	$17.07M
Total Liabilities	$8.420M	$10.04M	$38.52M
YoY Change	-79.62%	-73.93%
SHAREHOLDERS EQUITY
Retained Earnings	-$221.5M	-$214.8M
YoY Change	16.72%
Common Stock	$27.00K	$27.00K
YoY Change	200.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$433.0K	$433.0K
YoY Change	0.0%
Treasury Stock Shares
Shareholders Equity	$19.47M	$24.03M	-$32.33M
YoY Change
Total Liabilities & Shareholders Equity	$27.89M	$34.07M	$6.189M
YoY Change	404.3%	450.53%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2022 Q3
OPERATING ACTIVITIES
Net Income	-$6.767M	-$5.345M	$4.909M
YoY Change	93.62%	-208.88%	-266.75%
Depreciation, Depletion And Amortization	$95.00K	$134.0K	$138.0K
YoY Change	-31.16%	-2.9%	-66.75%
Cash From Operating Activities	-$6.910M	-$3.355M	-$2.470M
YoY Change	355.2%	35.83%	-67.5%
INVESTING ACTIVITIES
Capital Expenditures	$243.0K	$272.0K	$33.00K
YoY Change		724.24%
Acquisitions
YoY Change
Other Investing Activities	-$13.70M
YoY Change
Cash From Investing Activities	-$13.94M	-$272.0K	-$33.00K
YoY Change		724.24%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$120.0K
YoY Change			-58.19%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	401.0K	6.359M	-329.0K
YoY Change	-26.42%	-2032.83%	21.4%
NET CHANGE
Cash From Operating Activities	-6.910M	-3.355M	-2.470M
Cash From Investing Activities	-13.94M	-272.0K	-33.00K
Cash From Financing Activities	401.0K	6.359M	-329.0K
Net Change In Cash	-20.45M	2.732M	-2.832M
YoY Change	2001.85%	-196.47%	-64.02%
FREE CASH FLOW
Cash From Operating Activities	-$6.910M	-$3.355M	-$2.470M
Capital Expenditures	$243.0K	$272.0K	$33.00K
Free Cash Flow	-$7.153M	-$3.627M	-$2.503M
YoY Change	371.21%	44.91%	-67.07%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent		usd
CY2023Q3	GNLX	Warrant Liabilities Current WarrantLiabilitiesCurrent		usd
CY2023Q3	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent		usd
CY2023Q3	us-gaap	Deferred Costs DeferredCosts		usd
CY2023Q3	us-gaap	Interest Payable Current InterestPayableCurrent		usd
CY2023Q3	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent		usd
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001231457
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2022Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest		usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest		usd
CY2023Q3	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization		usd
CY2023Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
CY2022Q3	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense		usd
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense		usd
CY2023Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2023Q3	GNLX	Gain On Forgiveness Of Paycheck Protection Program Loan Payable GainOnForgivenessOfPaycheckProtectionProgramLoanPayable		usd
CY2022Q3	GNLX	Gain On Forgiveness Of Paycheck Protection Program Loan Payable GainOnForgivenessOfPaycheckProtectionProgramLoanPayable		usd
	GNLX	Gain On Forgiveness Of Paycheck Protection Program Loan Payable GainOnForgivenessOfPaycheckProtectionProgramLoanPayable		usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	GNLX	Fair Value Of Restricted Stock Units FairValueOfRestrictedStockUnits		usd
	GNLX	Cost Of Stock Option Repricing CostOfStockOptionRepricing		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
	GNLX	Gain On Forgiveness Of Ppp Loan Payable GainOnForgivenessOfPppLoanPayable		usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt		usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	GNLX	Reclassification Of Deferred Offering Costs To Shareholders Equity ReclassificationOfDeferredOfferingCostsToShareholdersEquity		usd
	GNLX	Reclassification Of Warrant Liabilities To Shareholders Equity ReclassificationOfWarrantLiabilitiesToShareholdersEquity		usd
	GNLX	Conversion Of Convertible Notes Payable Accrued Interest And Loan Fees To Shareholders Equity ConversionOfConvertibleNotesPayableAccruedInterestAndLoanFeesToShareholdersEquity		usd
	GNLX	Conversion Of Preferred Stock To Common Stock ConversionOfPreferredStockToCommonStock		usd
	GNLX	Conversion Of Dividends Payable To Shareholders Equity ConversionOfDividendsPayableToShareholdersEquity		usd
	GNLX	Conversion Of Notes Payableshareholders And Accrued Interest To Shareholders Equity ConversionOfNotesPayableshareholdersAndAccruedInterestToShareholdersEquity		usd
CY2023Q3	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable		usd
CY2022Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable		usd
CY2023Q3	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent		usd
CY2023Q3	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent		usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber		shares
	GNLX	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Non Vested In Period Total Fair Value Beginning ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedInPeriodTotalFairValueBeginning		usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod		shares
	GNLX	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodTotalFairValue		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2022Q4	GNLX	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Cancelled SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceCancelled
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
CY2022Q4	GNLX	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Expired SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceExpired
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity Registrant Name EntityRegistrantName	GENELUX CORPORATION
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity File Number EntityFileNumber	001-41599
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	77-0583529
	dei	Entity Address Address Line1 EntityAddressAddressLine1	2625 Townsgate Road
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 230
	dei	Entity Address City Or Town EntityAddressCityOrTown	Westlake Village
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	91361
	dei	City Area Code CityAreaCode	(805)
	dei	Local Phone Number LocalPhoneNumber	267-9889
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
	dei	Trading Symbol TradingSymbol	GNLX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	26717676	shares
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	29869000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	397000	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1310000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1495000	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	31179000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1892000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1022000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	644000	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1779000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1335000	usd
CY2022Q4	us-gaap	Deferred Costs DeferredCosts	1568000	usd
CY2023Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	92000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	92000	usd
CY2023Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	2893000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	3639000	usd
CY2023Q3	us-gaap	Assets Assets	34072000	usd
CY2022Q4	us-gaap	Assets Assets	5531000	usd
CY2023Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	4009000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	6775000	usd
CY2023Q3	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	4101000	usd
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	2852000	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1178000	usd
CY2023Q3	GNLX	Accrued Interest Payable Director And Shareholders AccruedInterestPayableDirectorAndShareholders	38000	usd
CY2022Q4	GNLX	Accrued Interest Payable Director And Shareholders AccruedInterestPayableDirectorAndShareholders	3817000	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	170000	usd
CY2022Q4	GNLX	Warrant Liabilities Current WarrantLiabilitiesCurrent	169000	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	567000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	266000	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	108000	usd
CY2022Q4	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	992000	usd
CY2023Q3	GNLX	Convertible Notes Payable Past Due Current ConvertibleNotesPayablePastDueCurrent	40000	usd
CY2022Q4	GNLX	Convertible Notes Payable Past Due Current ConvertibleNotesPayablePastDueCurrent	105000	usd
CY2023Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	40000	usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	15407000	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	8755000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	31626000	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1289000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1164000	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	541000	usd
CY2022Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	8524000	usd
CY2023Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1289000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	9688000	usd
CY2023Q3	us-gaap	Liabilities Liabilities	10044000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	41314000	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	22000	usd
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	26657906	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	26657906	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	9126726	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9126726	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	27000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	9000	usd
CY2023Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	433333	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	433333	shares
CY2023Q3	us-gaap	Treasury Stock Value TreasuryStockValue	433000	usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	433000	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	239189000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	154401000	usd
CY2023Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	2000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	2000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-214757000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-189784000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	24028000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-35783000	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	34072000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5531000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11000000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	170000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11000000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2819000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2414000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8607000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6610000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2488000	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2242000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8727000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4309000	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	5307000	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	4656000	usd
	us-gaap	Operating Expenses OperatingExpenses	17334000	usd
	us-gaap	Operating Expenses OperatingExpenses	10919000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-5307000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	6344000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-17164000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	81000	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	4000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	4000	usd
CY2022Q3	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	286000	usd
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	167000	usd
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	859000	usd
CY2022Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	49000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	649000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	148000	usd
CY2023Q3	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	42000	usd
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	3152000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-402000	usd
	GNLX	Gain On Forgiveness Of Paycheck Protection Program Loan Payable GainOnForgivenessOfPaycheckProtectionProgramLoanPayable	-314000	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-38000	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-335000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4366000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-693000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5345000	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	6009000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-21530000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-612000	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1100000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1100000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-5345000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	4909000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-21530000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1712000	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.20
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.54
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.91
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	26210068	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9117596	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23640995	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9113039	shares
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.20
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.49
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.91
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	26210068	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	10073788	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23640995	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	9113039	shares
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	22256000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	515000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3500000	usd
CY2023Q3	GNLX	Stock Issued During Perioid Fair Value Of Vested Restricted Stock Units StockIssuedDuringPerioidFairValueOfVestedRestrictedStockUnits	147000	usd
CY2023Q3	GNLX	Adjustments To Additional Paid In Capital Cost Of Stock Option Repricing AdjustmentsToAdditionalPaidInCapitalCostOfStockOptionRepricing	25000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	42000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1321000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	1567000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-5345000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	24028000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-35783000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	982000	usd
	GNLX	Issuance Of Common Shares Upon Closing Of Initial Public Offering Net Of Offering Costs IssuanceOfCommonSharesUponClosingOfInitialPublicOfferingNetOfOfferingCosts	12632000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	25142000	usd
	GNLX	Issuance Of Common Shares Upon Conversion Of Convertible Notes Payable Accrued Interest And Loan Fees IssuanceOfCommonSharesUponConversionOfConvertibleNotesPayableAccruedInterestAndLoanFees	29896000	usd
	GNLX	Stock Issued During Perioid Fair Value Of Vested Restricted Stock Units StockIssuedDuringPerioidFairValueOfVestedRestrictedStockUnits	774000	usd
	GNLX	Adjustments To Additional Paid In Capital Cost Of Stock Option Repricing AdjustmentsToAdditionalPaidInCapitalCostOfStockOptionRepricing	2667000	usd
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	169000	usd
	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	3152000	usd
	GNLX	Conversion Of Notes Payableshareholders And Accrued Interest ConversionOfNotesPayableshareholdersAndAccruedInterest	1865000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1321000	usd
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	2741000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-21530000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	24028000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-39063000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1703000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	120000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	4909000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-32331000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-33111000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-33111000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2372000	usd
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	120000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1712000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1712000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-32331000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-32331000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-21530000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1712000	usd
	us-gaap	Depreciation Depreciation	404000	usd
	us-gaap	Depreciation Depreciation	415000	usd
	GNLX	Rightofuse Asset RightofuseAsset	413000	usd
	GNLX	Rightofuse Asset RightofuseAsset	309000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	649000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	148000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	982000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2372000	usd
	GNLX	Fair Value Of Restricted Stock Units FairValueOfRestrictedStockUnits	774000	usd
	GNLX	Cost Of Stock Option Repricing CostOfStockOptionRepricing	-2667000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-402000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	3152000	usd
	GNLX	Gain On Forgiveness Of Ppp Loan Payable GainOnForgivenessOfPppLoanPayable	-314000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-185000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	164000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2133000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	890000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	1249000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	92000	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	22000	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	634000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-170000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-4440000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-431000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-283000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13365000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2053000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	782000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	49000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-782000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-49000	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	900000	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	685000	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	130000	usd
	GNLX	Payment Of Deferred Offering Costs PaymentOfDeferredOfferingCosts	303000	usd
	GNLX	Payment Of Deferred Offering Costs PaymentOfDeferredOfferingCosts	1013000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1321000	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	2741000	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	120000	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	14503000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	25142000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	43619000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1023000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	29472000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3125000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	397000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4495000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	29869000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1370000	usd
	us-gaap	Interest Paid Net InterestPaidNet	72000	usd
	us-gaap	Interest Paid Net InterestPaidNet	224000	usd
	GNLX	Extension Of Rightofuse Asset And Operating Lease ExtensionOfRightofuseAssetAndOperatingLease	845000	usd
	GNLX	Extension Of Rightofuse Asset And Operating Lease ExtensionOfRightofuseAssetAndOperatingLease	686000	usd
	GNLX	Reclassification Of Deferred Offering Costs To Shareholders Equity ReclassificationOfDeferredOfferingCostsToShareholdersEquity	1871000	usd
	GNLX	Reclassification Of Warrant Liabilities To Shareholders Equity ReclassificationOfWarrantLiabilitiesToShareholdersEquity	169000	usd
	GNLX	Conversion Of Convertible Notes Payable Accrued Interest And Loan Fees To Shareholders Equity ConversionOfConvertibleNotesPayableAccruedInterestAndLoanFeesToShareholdersEquity	29896000	usd
	GNLX	Conversion Of Preferred Stock To Common Stock ConversionOfPreferredStockToCommonStock	22000	usd
	GNLX	Conversion Of Dividends Payable To Shareholders Equity ConversionOfDividendsPayableToShareholdersEquity	3443000	usd
	GNLX	Conversion Of Notes Payableshareholders And Accrued Interest To Shareholders Equity ConversionOfNotesPayableshareholdersAndAccruedInterestToShareholdersEquity	1463000	usd
	us-gaap	Basis Of Accounting BasisOfAccounting	<p id="xdx_80B_eus-gaap--BasisOfAccounting_zA4OlkPqsXAc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 – <span id="xdx_824_zNuv10RZTGve">BASIS OF PRESENTATION</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Organization and Operations</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Genelux Corporation (“Genelux” or the “Company”), a Delaware Corporation, incorporated on September 4, 2001, is a biomedical company located in Westlake Village, California. The Company is engaged in the research and development of diagnostic and therapeutic solutions for cancer for which there is no effective treatment today. The Company is focused on the development of therapeutic approaches for cancer that are designed to generate a personalized multi-prong attack to overwhelm a tumor’s sophisticated defense mechanisms.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis of Presentation of Unaudited Financial Information</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited condensed financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all normal recurring adjustments considered necessary for a fair presentation have been included. Operating results for the nine months ended September 30, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity and Capital Resources</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying condensed financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2022, the Company incurred a net loss of $<span id="xdx_90B_eus-gaap--NetIncomeLoss_iN_pn3n3_di_c20220101__20221231_zF3UIYym3io4" title="Net income (loss)">5,207</span> and used cash in operations of $<span id="xdx_90A_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn3n3_di_c20220101__20221231_zOSn5aTfpoI1" title="Cash used in operations">3,571</span> and had a shareholders’ deficit of $<span id="xdx_905_eus-gaap--StockholdersEquity_iNI_pn3n3_di_c20221231_zxHcy9HZuCad" title="Shareholders' deficit">35,783</span> as of December 31, 2022. As reflected in the accompanying condensed financial statements, during the nine months ended September 30, 2023, the Company incurred a net loss of $<span id="xdx_90B_eus-gaap--NetIncomeLoss_iN_pn3n3_di_c20230101__20230930_zQGoHd880U56" title="Net income (loss)">21,530</span> and used cash in operations of $<span id="xdx_90A_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn3n3_di_c20230101__20230930_zkZBW9THjAI5" title="Cash used in operations">13,365</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the nine months ended September 30, 2023, the Company closed its initial public offering (“IPO”) and the two Private Placements (see Note 9) and received $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn3n3_c20230101__20230930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zePGV49fuTJg" title="Net proceeds">37,774 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of net proceeds from these offerings. At September 30, 2023, the Company had cash and cash equivalents on hand in the amount of $<span id="xdx_903_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_c20230930_zBsVdP0NIzgl" title="Cash and cash equivalents on hand">29,869</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The Company also received commitments through the Private Placements for the funding of an additional $<span id="xdx_909_ecustom--AdditionalCommitmentsReceived_iI_pn3n3_c20230930_z4RIbQvJ7USj" title="Additional commitments received">24,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Initially the additional funds were to be received by November 15, 2023, but, in November 2023, the Company agreed to extend the funding deadline for $<span id="xdx_902_eus-gaap--Investments_iI_pn3n3_c20231130__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardDateAxis__custom--MarchThirtyOneTwoThousandTwentyFourMember_zYUG4JeR8MCf">2,000 </span>of the remaining committed investment amounts to March 31, 2024. The investor who was obligated to fund $<span id="xdx_90E_eus-gaap--Investments_iI_pn3n3_c20231130__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_ziZyGfmjvZ9h">22,000</span> of the remaining committed investment amounts has not made such payments and has indicated that he does not intend to comply with his investment commitments through the Private Placements. We are currently evaluating our potential remedies with respect to this investor’s non-compliance with his contractual obligations to us. Due to the funds received through these offerings, and the conversion of preferred stock and convertible notes payable upon the closing of the IPO, the Company had shareholders’ equity of $<span id="xdx_90E_eus-gaap--StockholdersEquity_iI_pn3n3_c20230930_z43F60XE9R5l" title="Shareholders' equity">24,028</span> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at September 30, 2023. The Company expects its cash on hand at September 30, 2023 will last for at least the next 12 months.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The ability to continue as a going concern is dependent on the Company attaining and maintaining profitable operations in the future and raising additional capital to meet its obligations and repay its liabilities arising from normal business operations when they come due. Since inception, the Company has funded its operations primarily through equity and debt financings, and licensing income, and it expects to continue to rely on these sources of capital in the future.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to the Company. Even if the Company is able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing, or cause substantial dilution for our stockholders, in case of equity financing, or grant unfavorable terms in licensing future licensing agreements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reverse Stock Split</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2022, the Company effected a <span id="xdx_907_eus-gaap--StockholdersEquityReverseStockSplit_c20220801__20220831_zdwxGKH4sJfd" title="Reverse stock split">1-for-3 reverse stock split</span> of its common stock. The par value and the authorized shares of the common stock were not adjusted as a result of the reverse stock split. The reverse stock split resulted in an adjustment to the conversion prices of the convertible preferred stock to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion. The accompanying financial statements and notes to the financial statements give retroactive effect to the reverse stock split for all periods presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-5207000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3571000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-35783000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-21530000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13365000	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	29869000	usd
CY2023Q3	GNLX	Additional Commitments Received AdditionalCommitmentsReceived	24000000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	24028000	usd
CY2022Q3	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-3 reverse stock split
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84A_eus-gaap--UseOfEstimates_zUuNOVcHEKb8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zxiAzNfwUrN2">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date and reported amounts of revenue and expenses during the reporting period. Significant estimates are used in the valuation of accruals for potential liabilities, valuations of stock-based compensation, and realization of deferred tax assets, among others. Actual results could differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3354000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2950000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1022000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	644000	usd
	us-gaap	Depreciation Depreciation	404000	usd
	us-gaap	Depreciation Depreciation	415000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1335000	usd
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	27000	usd
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	27000	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5844308	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16058398	shares
CY2023Q3	us-gaap	Deferred Offering Costs DeferredOfferingCosts	303000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4376000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3594000	usd
	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	385000	usd
CY2023Q3	us-gaap	Accrued Payroll Taxes Current And Noncurrent AccruedPayrollTaxesCurrentAndNoncurrent	1436000	usd
CY2023Q3	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	4101000	usd
CY2018Q3	us-gaap	Payments For Rent PaymentsForRent	10000	usd
CY2018Q3	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	option to extend for an additional five years
CY2018Q3	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.0400	pure
CY2022Q2	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	the option to extend the lease for an additional five years
CY2018Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	174000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	860000	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	860000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.0400	pure
CY2022Q2	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	686000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	extended the lease for an additional two-year period, through September 2030, with no changes to any of the other terms of the lease, and has the option to extend the lease for an additional five years. Prior to the extension, the remaining lease liability amounted to $701
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	909000	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	909000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.0700	pure
CY2023Q3	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	208000	usd
CY2020Q4	us-gaap	Payments For Rent PaymentsForRent	18000	usd
CY2020Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.0400	pure
CY2023Q1	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	extended the lease through December 2024, with no changes to any of the other terms of the lease
CY2023Q1	us-gaap	Payments For Rent PaymentsForRent	30000	usd
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	12000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	649000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.055	pure
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	637000	usd
CY2021Q3	us-gaap	Payments For Rent PaymentsForRent	10000	usd
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	656000	usd
CY2021Q3	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.0400	pure
	us-gaap	Operating Lease Payments OperatingLeasePayments	431000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	283000	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	1856000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1430000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	413000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	309000	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1779000	usd
CY2022Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1100000	usd
CY2022	GNLX	Debt Instrument Accrued And Unpaid Interest DebtInstrumentAccruedAndUnpaidInterest	5000	usd
CY2023Q3	us-gaap	Short Term Borrowings ShortTermBorrowings	900000	usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	600000	usd
CY2023Q3	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	11000	usd
	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	1400	usd
	us-gaap	Debt Instrument Periodic Payment Interest DebtInstrumentPeriodicPaymentInterest	63000	usd
	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	73134	shares
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	1865000	usd
	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	69000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-402000	usd
	GNLX	Description Of Warrants DescriptionOfWarrants	Company issued the note holders stock warrants to purchase up to an aggregate total of 44,441 shares of its common stock with an exercise price per share equal to 90% of the IPO price, or $5.40 per share, based on the IPO closing price
CY2023Q3	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	169000	usd
CY2022	GNLX	Amortization Of Debt Discount AmortizationOfDebtDiscount	61000	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	108000	usd
	GNLX	Amortization Of Debt Discount AmortizationOfDebtDiscount	108000	usd
CY2023Q3	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	40000	usd
CY2022Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	15407000	usd
CY2023Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	40000	usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	15407000	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	541000	usd
CY2022Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	8524000	usd
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	29927994	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	22094889	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	22094889	shares
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	22095
CY2023Q1	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	8355610	shares
CY2023Q1	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	991172	shares
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	29927994	shares
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	26657906	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	26657906	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	9126726	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9126726	shares
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q3	us-gaap	Investment Owned At Cost InvestmentOwnedAtCost	6000	usd
CY2023Q3	us-gaap	Investment Owned At Fair Value InvestmentOwnedAtFairValue	30000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	171400	shares
	GNLX	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue	2043000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	11.92
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	113500	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	774000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	6.57
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	57900	shares
	GNLX	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Non Options Vested In Period Total Fair Value Ending ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanNonOptionsVestedInPeriodTotalFairValueEnding	1269000	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	22.40
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	774000	usd
	GNLX	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested In Period Total Fair Value Ending ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedInPeriodTotalFairValueEnding	1269000	usd
	GNLX	Fair Market Value Of Shares Percentage Description FairMarketValueOfSharesPercentageDescription	(i) 100% of the fair market value of a share of stock on the grant date, or (ii) 110% of the fair market value of a share of stock on the grant date in the case of a Participant then owning more than 10% of the total combined voting power of all classes of stock of the Company or any “subsidiary corporation” of the Company or any “parent corporation” of the Company.
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	22.40
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.000	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.044	pure
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	982000	usd
CY2023Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	21385000	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	73438000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4201019	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.09
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1103938	shares
CY2022Q4	GNLX	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Granted SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceGranted	22.40
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	22.40
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	207303	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	6.39
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5097654	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.61
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	3828435	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	6.08
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	1269219	shares
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	20.26
CY2022Q3	GNLX	Repricing Costs RepricingCosts	2733000	usd
	GNLX	Repricing Costs RepricingCosts	2667000	usd
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	207303	shares
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1321000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	725174	shares
CY2022Q4	GNLX	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	8.24
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	447906	shares
	GNLX	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice	7.87
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures	36	shares
	GNLX	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeited Exercise Price Range ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedExercisePriceRange	9.00
	GNLX	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeited Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedWeightedAverageExercisePrice	9.00
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	479708	shares
	GNLX	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice	8.31
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations	4762	shares
	GNLX	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expired Exercise Price Range ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredExercisePriceRange	10.50
	GNLX	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expired Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredWeightedAverageExercisePrice	10.50
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	688574	shares
CY2023Q3	GNLX	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	7.94
CY2023Q3	GNLX	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	688574	shares
CY2023Q3	GNLX	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice	7.94
CY2023Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	217591	shares
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2173000	usd
CY2023Q3	GNLX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue	10487000	usd

Files In Submission

Name	View Source	Status
gnlx-20230930_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
0001493152-23-041151-index-headers.html	Edgar Link	pending
0001493152-23-041151-index.html	Edgar Link	pending
0001493152-23-041151.txt	Edgar Link	pending
0001493152-23-041151-xbrl.zip	Edgar Link	pending
ex10-1.htm	Edgar Link	pending
ex10-1_001.jpg	Edgar Link	pending
ex10-2.htm	Edgar Link	pending
ex10-3.htm	Edgar Link	pending
ex10-4.htm	Edgar Link	pending
ex10-5.htm	Edgar Link	pending
ex10-6.htm	Edgar Link	pending
ex10-7.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
gnlx-20230930.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
gnlx-20230930_cal.xml	Edgar Link	unprocessable
gnlx-20230930_pre.xml	Edgar Link	unprocessable
gnlx-20230930_lab.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GNLX
GENELUX Corp Stock $gnlx

2023 Q4 Form 10-Q Financial Statement

#000149315223041151 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GNLX GENELUX Corp Stock $gnlx

2023 Q4 Form 10-Q Financial Statement

#000149315223041151 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GNLX
GENELUX Corp Stock $gnlx